Literature DB >> 17010957

Innate immunity and inflammation--New frontiers in comparative cardiovascular pathology.

Annika Linde1, Derek Mosier, Frank Blecha, Tonatiuh Melgarejo.   

Abstract

Innate immunity and inflammation play key roles in a wide range of pathology - including heart disease and vasculopathies. Current thinking suggests "damage" rather than "foreignness" as the actual trigger of the immune system, which has caused a dramatic change in how we tend to view the etiopathology of most types of heart disease. The future potential of certain anti-inflammatory therapeutic strategies in addressing heart disease is intriguing. Still, the Janus face of immunity/inflammation cannot be over emphasized as adverse manipulation of these systems may prove ineffectual or worse, damaging. Knowledge on functional characteristics of individual immune mediators is undoubtedly a central theme, but in depth understanding of the multiple biological actions of these molecules, as well as their contextual function, is the corner stone in deciding on potential future targets for pharmacologic manipulation. Animal models of human heart disease are currently being investigated and clinical trials conducted to gain further knowledge in this essential area of cardiovascular research, but the scarcity of cardiovascular research focusing on signaling molecules and pathways of innate immunity is still evident. Genomic and proteomic research in heart disease is going through its formative years, and much is still unknown about the complex pathway dynamics utilized by the innate immune system. This review will provide an overview of the current literature focusing on innate immunity and the heart, and hopefully will spark an interest in further basic as well as clinical research. As more information on cardiovascular immunity becomes available, this will provide a better understanding and thus act as the foundation for potential development of new treatment strategies for treatment of cardiovascular disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010957     DOI: 10.1016/j.cardiores.2006.08.009

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  29 in total

1.  The role of nitric oxide in regulation of leukocyte migration into the heart tissue in vitro.

Authors:  A A Petenkova; R I Kovalenko; A D Nozdrachev
Journal:  Dokl Biol Sci       Date:  2016-01-05

2.  Natural History of Innate Host Defense Peptides.

Authors:  A Linde; B Wachter; O P Höner; L Dib; C Ross; A R Tamayo; F Blecha; T Melgarejo
Journal:  Probiotics Antimicrob Proteins       Date:  2009-12       Impact factor: 4.609

Review 3.  Toll-like receptors: new players in myocardial ischemia/reperfusion injury.

Authors:  Tuanzhu Ha; Li Liu; Jim Kelley; Race Kao; David Williams; Chuanfu Li
Journal:  Antioxid Redox Signal       Date:  2011-04-08       Impact factor: 8.401

4.  Cyclic stretch enhances the expression of toll-like receptor 4 gene in cultured cardiomyocytes via p38 MAP kinase and NF-kappaB pathway.

Authors:  Kou-Gi Shyu; Bao-Wei Wang; Chiu-Mei Lin; Hang Chang
Journal:  J Biomed Sci       Date:  2010-03-05       Impact factor: 8.410

5.  Protective effect of miR-20a against hypoxia/reoxygenation treatment on cardiomyocytes cell viability and cell apoptosis by targeting TLR4 and inhibiting p38 MAPK/JNK signaling.

Authors:  Xin-Yu Gong; Yun Zhang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-08-23       Impact factor: 2.416

6.  TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism.

Authors:  Tuanzhu Ha; Yulong Hu; Li Liu; Chen Lu; Julie R McMullen; Jim Kelley; Race L Kao; David L Williams; Xiang Gao; Chuanfu Li
Journal:  Cardiovasc Res       Date:  2010-04-26       Impact factor: 10.787

Review 7.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

8.  MicroRNA-125b protects against myocardial ischaemia/reperfusion injury via targeting p53-mediated apoptotic signalling and TRAF6.

Authors:  Xiaohui Wang; Tuanzhu Ha; Jianghuan Zou; Danyang Ren; Li Liu; Xia Zhang; John Kalbfleisch; Xiang Gao; David Williams; Chuanfu Li
Journal:  Cardiovasc Res       Date:  2014-02-27       Impact factor: 10.787

Review 9.  Viral myocarditis: from experimental models to molecular diagnosis in patients.

Authors:  Sabine Pankuweit; Karin Klingel
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

10.  Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury.

Authors:  Xiaohui Wang; Tuanzhu Ha; Li Liu; Jianghuan Zou; Xia Zhang; John Kalbfleisch; Xiang Gao; David Williams; Chuanfu Li
Journal:  Cardiovasc Res       Date:  2012-12-03       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.